Previous 10 | Next 10 |
New York, New York--(Newsfile Corp. - April 12, 2019) - Genprex Inc. (NASDAQ: GNPX) announces the availability of a NetworkNewsAudio broadcast titled, " Potential Blockbuster Gene Therapy Programs to Watch in 2019 ." To hear the NetworkNewsWire Audio version, visit: http://nnw.fm/j1WMs ...
NEW YORK, April 12, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio -- Genprex Inc. (NASDAQ:GNPX) announces the availability of a NetworkNewsAudio broadcast titled, “ Potential Blockbuster Gene Therapy Programs to Watch in 2019 .” To hear the NetworkNewsWire Audio ver...
New York, New York--(Newsfile Corp. - April 11, 2019) - Genprex Inc. (NASDAQ: GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for private and public entities. To view the full publication, titled ...
NEW YORK, April 11, 2019 (GLOBE NEWSWIRE) -- via NetworkWire — Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for private and public entities. To view the full ...
NetworkNewsWire Editorial Coverage : Several revolutionary gene therapies appear to be on the verge of delivering remarkable remedies for diseases that have previously been viewed as untreatable. Gene therapy is the next great leap forward in medicine, with several noteworthy programs u...
Clinical-stage gene therapy company Genprex Inc. (NASDAQ: GNPX) this morning announced that its collaborators from the University of Texas MD Anderson Cancer Center (“MD Anderson”) detailed positive preclinical data, in a poster presented at the American Association of Cancer R...
TUSC2 Immunogene Therapy Overcomes Resistance to Checkpoint Blockade Genprex, Inc. (NASDAQ: GNPX ), a clinical-stage gene therapy company, reported that its collaborators from The University of Texas MD Anderson Cancer Center (“MD Anderson”) presented positive preclin...
Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) on Monday provided a clinical, corporate and financial update for the year ended December 31, 2018. Among other highlights, Genprex reached various milestones in 2018 and early 2019 which included completing its initial public offeri...
Genprex (NASDAQ: GNPX ): FY GAAP EPS of -$0.90. More news on: Genprex, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Genprex, Inc. (NASDAQ: GNPX ), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced a clinical and corporate update and the filing of financial results for the year ended December 31, 2018 on...
News, Short Squeeze, Breakout and More Instantly...
Genprex to Present at the 2024 BIO International Convention PR Newswire Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , May 30, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: ...
Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer PR Newswire Expects to Initiate the Phase 2 Expansion Study in the Second Half of 2024 Acclaim-3 Study Suppor...